Industry Pulse › FDA Moves to Ban Compounded Semaglutide and Tirzepatide May 1, 2026 · Regulatory On May 1, 2026, the FDA filed a proposal that would effectively end large-scale compounding of semaglutide, tirzepatide, and liraglutide in the United States. These are the active ingredients in Ozempic, Wegovy, Mounjaro, Zepbound, Victoza, and Saxenda. If the …
More
FDA Moves to Ban Compounded Semaglutide and Tirzepatide: What Researchers Need to Know
Beyond Ozempic and Mounjaro: A Five-Target Obesity Drug Just Outperformed Both
A research team at Helmholtz Zentrum München has published the design of a single-molecule quintuple agonist that activates GLP-1, GIP, and three PPAR receptor subtypes. Published in Nature on April 30, 2026, the conjugate outperformed semaglutide and tirzepatide dual agonism in obese diabetic mouse models.
More